BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jacobson C, Lacasce A. How I treat Burkitt lymphoma in adults. Blood 2014;124:2913-20. [DOI: 10.1182/blood-2014-06-538504] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Burkhardt B, Lenz G. XI. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other? Hematol Oncol 2015;33 Suppl 1:62-6. [PMID: 26062057 DOI: 10.1002/hon.2219] [Reference Citation Analysis]
2 Della Rocca AM, Leonart LP, Ferreira VL, Tonin FS, Steffenello-Durigon G, Del Moral JAG, Fernandez-Llimos F, Pontarolo R. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies. Clin Lymphoma Myeloma Leuk 2021;21:514-25. [PMID: 33947633 DOI: 10.1016/j.clml.2021.03.012] [Reference Citation Analysis]
3 Soyland DJ, Thanel PF, Sievers ME, Wagner K, Vuong SM. Primary epidural sporadic Burkitt lymphoma in a 3-year-old: Case report and literature review. Surgical Neurology International 2022;13:106. [DOI: 10.25259/sni_1172_2021] [Reference Citation Analysis]
4 Viotto CT, Simões NN, Borges ACO, Torresan C. Primary pediatric Burkitt's lymphoma of both femurs-case report. Hematol Transfus Cell Ther 2020:S2531-1379(20)30276-5. [PMID: 33039384 DOI: 10.1016/j.htct.2020.08.010] [Reference Citation Analysis]
5 Khan A, Brahim A, Ruiz M, Nagovski N. Relapsed/refractory Burkitt lymphoma and HIV infection. Int J STD AIDS 2018;29:695-703. [PMID: 29264956 DOI: 10.1177/0956462417748239] [Reference Citation Analysis]
6 Alzahrani M, Al-Mansour MM, Apostolidis J, Barefah A, Dada R, Alhejazi A, Alayed Y, Motabi I, Radwi M, Al-Hashmi H. Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up of Patients with Various Types of Lymphoma during the Coronavirus Disease 2019 Pandemic. Saudi J Med Med Sci 2020;8:227-38. [PMID: 32952517 DOI: 10.4103/sjmms.sjmms_457_20] [Reference Citation Analysis]
7 Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 2017;92:E114-7. [PMID: 28295472 DOI: 10.1002/ajh.24720] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
8 Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood 2018;132:254-63. [PMID: 29769263 DOI: 10.1182/blood-2018-04-844472] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
9 Della Rocca AM, Tonin FS, Fachi MM, Cobre AF, Ferreira VL, Leonart LP, Steffenello-Durigon G, Del Moral JAG, Lenzi L, Pontarolo R. Prognostic Factors, Survival Analyses and the Risk of Second Primary Cancer: A Population-Based Study on Burkitt Lymphoma/Leukemia. Diseases 2021;9:43. [PMID: 34203748 DOI: 10.3390/diseases9020043] [Reference Citation Analysis]
10 Chen B, Chang S, Weng S, Huang W, Chu P, Hsieh P, Jung Y, Kuo C, Chuang Y, Chuang S. EBV-associated Burkitt lymphoma in Taiwan is not age-related. Leukemia & Lymphoma 2015;57:644-53. [DOI: 10.3109/10428194.2015.1076928] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
11 Khalili-Tanha G, Moghbeli M. Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cell Mol Biol Lett 2021;26:39. [PMID: 34425750 DOI: 10.1186/s11658-021-00282-9] [Reference Citation Analysis]
12 Ma X, Xu G, Li Z, Chen F, Wu D, Miao J, Zhan Y, Fan Y. HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt’s Lymphoma Cells by Impeding the Cell Cycle. CURR MED SCI 2019;39:228-36. [DOI: 10.1007/s11596-019-2024-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Guo C, Gong M, Li Z. Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a/EIF4E Axis. Cancer Manag Res 2020;12:5845-55. [PMID: 32765087 DOI: 10.2147/CMAR.S248698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021;137:374-86. [PMID: 32663292 DOI: 10.1182/blood.2020006926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Flümann R, Nieper P, Reinhardt HC, Knittel G. New murine models of aggressive lymphoma. Leuk Lymphoma 2020;61:788-98. [PMID: 31752573 DOI: 10.1080/10428194.2019.1691200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 de Souza Fernandes Pereira M, Fantacini DMC, Picanço-Castro V. Generation of Tumor Cells Expressing Firefly Luciferase (fLuc) to Evaluate the Effectiveness of CAR in a Murine Model. Methods Mol Biol 2020;2086:237-50. [PMID: 31707681 DOI: 10.1007/978-1-0716-0146-4_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Wang N, Zeng GZ, Yin JL, Bian ZX. Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma. Biochem Biophys Res Commun 2019;519:533-9. [PMID: 31537387 DOI: 10.1016/j.bbrc.2019.09.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
18 Zhu H, Long MH, Wu J, Wang MM, Li XY, Shen H, Xu JD, Zhou L, Fang ZJ, Luo Y, Li SL. Ginseng alleviates cyclophosphamide-induced hepatotoxicity via reversing disordered homeostasis of glutathione and bile acid. Sci Rep 2015;5:17536. [PMID: 26625948 DOI: 10.1038/srep17536] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
19 Crombie JL, LaCasce AS. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. Front Oncol 2019;9:109. [PMID: 30899698 DOI: 10.3389/fonc.2019.00109] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
20 Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM. Burkitt Lymphoma International Prognostic Index. J Clin Oncol 2021;39:1129-38. [PMID: 33502927 DOI: 10.1200/JCO.20.03288] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther 2017;8:11-29. [PMID: 28096698 DOI: 10.2147/AHMT.S94170] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
22 Havelange V, Pepermans X, Ameye G, Théate I, Callet-bauchu E, Barin C, Penther D, Lippert E, Michaux L, Mugneret F, Dastugue N, Raphaël M, Vikkula M, Poirel HA. Genetic differences between paediatric and adult Burkitt lymphomas. Br J Haematol 2016;173:137-44. [DOI: 10.1111/bjh.13925] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
23 Migdady Y, Salhab M, Dang NH, Markham MJ, Olszewski AJ. Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. Leuk Lymphoma 2016;57:676-84. [PMID: 26428541 DOI: 10.3109/10428194.2015.1102246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
24 Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, Tirumani SH. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging 2019;10:56. [PMID: 31115699 DOI: 10.1186/s13244-019-0733-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
25 Konjeti VR, Hefferman GM, Paluri S, Ganjoo P. Primary Pancreatic Burkitt's Lymphoma: A Case Report and Review of the Literature. Case Rep Gastrointest Med 2018;2018:5952315. [PMID: 29593916 DOI: 10.1155/2018/5952315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Jain A, Arun VA, Bal A, Malhotra P. Primary chest wall Burkitt lymphoma in a case of HIV infection with immune reconstitution. BMJ Case Rep 2021;14:e243873. [PMID: 34969787 DOI: 10.1136/bcr-2021-243873] [Reference Citation Analysis]
27 Buege MJ, Dao PH, Drill E, LeVoir A, Pak T, Peterson TJ, Straus DJ. IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00306-2. [PMID: 34413005 DOI: 10.1016/j.clml.2021.07.024] [Reference Citation Analysis]
28 Wang L, Wang H, Xia ZJ, Huang HQ, Jiang WQ, Lin TY, Lu Y. Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma. Ann Hematol 2015;94:1645-54. [PMID: 26082333 DOI: 10.1007/s00277-015-2427-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
29 Wang Z, Chen M, Fang X, Hong H, Yao Y, Huang H. KIF15 is involved in development and progression of Burkitt lymphoma. Cancer Cell Int 2021;21:261. [PMID: 33985517 DOI: 10.1186/s12935-021-01967-z] [Reference Citation Analysis]
30 Zayac AS, Olszewski AJ. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. Leuk Lymphoma 2020;61:1784-96. [PMID: 32255708 DOI: 10.1080/10428194.2020.1747068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
31 Höring E, Staiger AM, Lenze D, Horn H, Vöhringer M, Steurer W, Aulitzky WE, Ott G. Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. Leuk Lymphoma 2018;59:249-52. [PMID: 28583033 DOI: 10.1080/10428194.2017.1330469] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Shah MR, Brandt JS, David KA, Evens AM. Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches. Curr Oncol Rep 2020;22:113. [PMID: 32804274 DOI: 10.1007/s11912-020-00972-1] [Reference Citation Analysis]
33 Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. The Lancet 2017;390:298-310. [DOI: 10.1016/s0140-6736(16)32407-2] [Cited by in Crossref: 158] [Cited by in F6Publishing: 89] [Article Influence: 31.6] [Reference Citation Analysis]
34 Ni F, Huang X, Chen Z, Qian W, Tong X. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. Sci Rep 2018;8:3317. [PMID: 29463831 DOI: 10.1038/s41598-018-21570-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
35 Ma'koseh M, Amarin R, Tamimi F, Sharaf B, Abufara A, Shahin O, Manassra MKM, Halahleh K. Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan. Blood Res 2021;56:279-84. [PMID: 34880141 DOI: 10.5045/br.2021.2021116] [Reference Citation Analysis]
36 Lin Y, Pan YH, Li MK, Zong XD, Pan XM, Tan SY, Guo YW. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report. World J Gastroenterol 2021; 27(45): 7844-7854 [PMID: 34963746 DOI: 10.3748/wjg.v27.i45.7844] [Reference Citation Analysis]
37 Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood 2021;137:743-50. [PMID: 33171490 DOI: 10.1182/blood.2019004099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, Delabie J, Staudt LM, Song JY, McKeithan TW, Fu K, Green M, Chan WC, Iqbal J. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood 2017;130:1819-31. [PMID: 28801451 DOI: 10.1182/blood-2017-02-767335] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
39 Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol 2018;181:495-504. [PMID: 29687879 DOI: 10.1111/bjh.15224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
40 Tadipatri R, Gonzalez D, Muley S, Fonkem E, Azadi A. A Rare Case of Burkitt's Lymphoma Presenting With Features Mimicking Vogt-Koyanagi-Harada Disease. Cureus 2021;13:e17659. [PMID: 34646701 DOI: 10.7759/cureus.17659] [Reference Citation Analysis]
41 Tabata M, Tsubaki M, Takeda T, Tateishi K, Tsurushima K, Imano M, Satou T, Ishizaka T, Nishida S. Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells. BMC Complement Med Ther 2020;20:84. [PMID: 32171300 DOI: 10.1186/s12906-020-2879-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Krause G, Hassenrück F, Hallek M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther 2018;12:2577-90. [PMID: 30174412 DOI: 10.2147/DDDT.S142406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
43 Silva WFD, Garibaldi PMM, Rosa LID, Bellesso M, Clé DV, Delamain MT, Rego EM, Pereira J, Rocha V. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study. Leuk Res 2020;89:106287. [PMID: 31864677 DOI: 10.1016/j.leukres.2019.106287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Kasparian S, Burns E, Shehabeldin A, Awar M, Pingali SR. Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: a case report and review of the literature. J Med Case Rep 2020;14:127. [PMID: 32782017 DOI: 10.1186/s13256-020-02449-y] [Reference Citation Analysis]
45 Gordon MJ, Westin JR. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? Leuk Lymphoma 2021;:1-11. [PMID: 34842019 DOI: 10.1080/10428194.2021.2008383] [Reference Citation Analysis]
46 Avigdor A, Shouval R, Jacoby E, Davidson T, Shimoni A, Besser M, Nagler A. CAR T cells induce a complete response in refractory Burkitt Lymphoma. Bone Marrow Transplant 2018;53:1583-5. [PMID: 29795432 DOI: 10.1038/s41409-018-0235-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
47 Goldstein JS, Switchenko JM, Behera M, Flowers CR, Koff JL. Insurance status impacts overall survival in Burkitt lymphoma. Leuk Lymphoma 2019;60:3225-34. [PMID: 31274033 DOI: 10.1080/10428194.2019.1623884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Wang Y, Deng M, Chen Q, Li Y, Guo X, Shi P, He L, Xie S, Yu L, Zhang H, Xu B. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. Eur J Pharmacol 2019;843:145-53. [PMID: 30423319 DOI: 10.1016/j.ejphar.2018.11.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 Bekoz HS, Kantarcioglu B, Tecimer T, Uskent N, Cetiner M, Ferhanoglu B, Sargin D. Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report. Indian J Hematol Blood Transfus 2016;32:178-80. [PMID: 27408385 DOI: 10.1007/s12288-016-0650-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Abdelwahed Hussein MR. Non-Hodgkin’s lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint. Expert Review of Hematology 2018;11:737-48. [DOI: 10.1080/17474086.2018.1506326] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
51 Tan JY, Qiu TY, Chiang J, Tan YH, Yang VS, Chang EWY, Poon E, Somasundaram N, Farid M, Tao M, Lim ST, Chan JY. Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leukemia & Lymphoma. [DOI: 10.1080/10428194.2022.2027402] [Reference Citation Analysis]